mavatrep mavatrep mavatrep (jnj‐39439335) is a trpv1 receptor selective competitive antagonist. it is an investigational analgesic that may be a potential treatment for analgesia and/or inflammation. mavatrepclinical dataother namesjnj-39439335identifiers iupac name 2-ethenyl]-3h-benzimidazol-5-yl]phenyl]propan-2-ol cas number956274-94-5pubchem cid17751090drugbankdb12875chemspider29271895uniif197218t99chemblchembl2364618comptox dashboard (epa)dtxsid90241905 chemical and physical dataformulac25h21f3n2omolar mass422.451 g·mol−13d model (jsmol)interactive image smiles cc(c)(c1=cc=cc=c1c2=cc3=c(c=c2)n=c(n3)/c=c/c4=cc=c(c=c4)c(f)(f)f)o inchi inchi=1s/c25h21f3n2o/c1-24(2,31)20-6-4-3-5-19(20)17-10-13-21-22(15-17)30-23(29-21)14-9-16-7-11-18(12-8-16)25(26,27)28/h3-15,31h,1-2h3,(h,29,30)/b14-9+key:ordhxxhtbuzrcn-nteuormpsa-n phase i trials have been completed in healthy japanese and caucasian volunteers. potential common adverse effects include thermohypoesthesia, chills, feeling cold, and feeling hot. pharmacokinetics when administered orally once a day, mavatrep reached steady-state in healthy volunteers in approximately 14 days. it has a relatively long half life between 68–101 hours in japanese subjects and between 82–130 hours in caucasian subjects. mavatrep is largely eliminated nonrenally. mavatrep appears to be metabolized into two primary metabolites which are also eliminated nonrenally.